Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.
Choose a source to read (2)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
Professional source
NIH adult ARV table - single-agent abacavir
Product / population
Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Renal measure
Most ARV label thresholds use Cockcroft-Gault CrCl
Dosing / renal protocol and limits
Adults: 300 mg orally twice daily or 600 mg daily; no renal dose change. This single-agent statement must not be transferred to abacavir/lamivudine combinations. Child-Pugh A instead requires 200 mg twice daily using solution; B/C is contraindicated.
Source revision: Revision date not stated in the reviewed page. | Retrieved: 2026-09-05. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Preserved GlobalRPh source
Preserved original GlobalRPh source
Preserved historical content; not revalidated as current prescribing guidance.
Renal method: Read the measure and population stated in the original source sections. Retrieved: 2026-09-05
Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.
Find text within this drug
Find a term without leaving this drug
Search the stored clinical text
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. Searches stay on this page and are not saved or sent.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content
Original GlobalRPh protocol
Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/abacavir/
Usual Dosing (Adults)
Adults (usual): 300mg orally bid or 600 mg once daily in combination with other antiretroviral agents
NIH ClinicalInfo adult ARV panel · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Renal method: Most ARV label thresholds use Cockcroft-Gault CrCl Source date: Revision date not stated in the reviewed page. Retrieved: 2026-09-05
Locally included source-specific summary. Regimen differences are not automatically resolved.
Dosing / renal protocol and limits
Adults: 300 mg orally twice daily or 600 mg daily; no renal dose change. This single-agent statement must not be transferred to abacavir/lamivudine combinations. Child-Pugh A instead requires 200 mg twice daily using solution; B/C is contraindicated.
RDM30-098-abacavir-1 · Source locator: NIH adult ARV table - single-agent abacavir; renal/dosing sections and stated qualifiers
Additional summaries stored on this page: 0 official-label, 0 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.